<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancer.

ZFAS1 mRNA expression is associated with poor prognosis in stage II/III BRAFMT CC High gene expression of ZFAS1 was associated with a prognostic trend in BRAFMT tumors compared to low gene expression ( Supplementary Figure 4A ) although given the small number of events in this stratified group, this trend failed to reach significance in either unadjusted HR = 4.69 (95% CI 0.52–42.01), or adjusted HR = 4.71 (95% CI 0.50–44.00) analyses ( Supplementary Table 3 ).

also in 4,113 other papers